Pharmacotherapy for Dravet Syndrome

Keyphrases

• Pharmacotherapy 100%
• Dravet Syndrome 100%
• Encephalopathy 20%
• Pharmacological Therapy 10%
• Topiramate 10%
• Seizure 10%
• Levetiracetam 10%
• Lamotrigine 10%
• Carbamazepine 10%
• Quality of Life 10%
• Early childhood 10%
• Non-pharmacological Therapy 10%
• Sodium Channel 10%
• Mortality Rate 10%
• Gait Disorders 10%
• Attention Deficit Hyperactivity Disorder 10%
• Psychostimulants 10%
• Neurostimulation 10%
• Clinical Quality 10%
• Promising Treatment 10%
• Epilepsy Syndrome 10%
• Channel Blockage 10%
• Anticonvulsant 10%
• Valproate 10%
• Refractory Epilepsy 10%
• Pediatric Epilepsy 10%
• Fenfluramine 10%
• Pharmacologic Management 10%
• Clinical picture 10%
• Polytherapy 10%
• Ketogenic Diet 10%
• Nonepileptic 10%
• Epileptic Encephalopathy 10%
• Clobazam 10%
• Nonfebrile Seizure 10%
• Febrile Status Epilepticus 10%
• Stiripentol 10%
• Extrapyramidal Disorders 10%
• SCN1A Gene 10%
• Multifocal Epilepsy 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Pharmacotherapy 100%
• Severe Myoclonic Epilepsy in Infancy 100%
• Brain Disease 30%
• Syndrome 20%
• Diseases 20%
• Lamictal 10%
• Sodium Valproate 10%
• Clobazam 10%
• Psychostimulant 10%
• Carbamazepine 10%
• Attention Deficit Disorder 10%
• Epileptic State 10%
• Drug Resistant Epilepsy 10%
• Anticonvulsive Agent 10%
• Gait Disorder 10%
• Mortality Rate 10%
• Psychotropic Agent 10%
• Intractable Epilepsy 10%
• Extrapyramidal Syndrome 10%
• Febrile Convulsion 10%
• Stiripentol 10%
• Sodium Channel 10%
• Combination Therapy 10%
• Topiramate 10%
• Levetiracetam 10%
• Fenfluramine 10%